Prior Authorization Requirements for Specialty Medications: What to Check Before Each Request

If you've spent any time managing prior authorizations for specialty medications, you already know the drill: just when you think you've got a payer's requirements figured out, something shifts. Payers revise their criteria for high-cost specialty drugs on their own schedules, and the practices that check current criteria before each request spend less time fighting denials later. Let's walk through what to check, what it means for your workflows, and how to keep your patients' medications from getting interrupted.

What to Check Before Your Next Request

Payers don't change their criteria on one shared date. Each plan revises its own criteria for high-cost categories such as biologics for inflammatory conditions (rheumatoid arthritis, psoriasis, Crohn's disease), targeted and supportive oncology agents, and GLP-1 receptor agonists prescribed beyond type 2 diabetes. Before each request, confirm these points against the plan's current policy:

• Step therapy. How many conventional therapies the policy requires the patient to have tried, for how long and at what dose. If you've been submitting with one prior therapy documented, check that the current criteria don't ask for more.
• Biomarker or genetic testing. Many targeted oncology agents are approved for tumors with a specific biomarker, and policies for them ask for the test result, so a diagnosis code alone won't meet the criteria. Attach the test report to the initial submission.
• GLP-1s for weight management. Whether the plan covers the weight-management indication at all, and if it does, the BMI threshold, comorbidities and prior weight-loss efforts the policy asks you to document.
• Reauthorization. How long an approval lasts and what the renewal request must show. Approval periods vary by plan and drug, so put the end date on the calendar when the approval arrives.

If many of your specialty patients are on Medicare Advantage plans, note that the CMS-0057-F decision timeframes that took effect January 1, 2026 (7 calendar days for standard requests, 72 hours for expedited ones) exclude drugs. A request to an MA plan for a Part B drug already has shorter deadlines: 72 hours for a standard request and 24 hours for an expedited one (42 CFR 422.568, 42 CFR 422.572). Part D drug requests follow the Part D coverage determination and exception rules.

The Documentation Mistakes That Are Costing You Approvals

Here's a common pattern: practices submit complete clinical information, and they still get denied. The patient qualifies, but the documentation doesn't speak the payer's language. There's a difference between documenting that a patient "tried methotrexate without adequate response" and documenting that a patient "completed a 12-week trial of methotrexate at therapeutic doses with persistent disease activity as measured by [specific scale], documented on [dates]."

The second version is what payers want. The first version gets you a denial letter that says "insufficient documentation of step therapy failure."

A few specific documentation tips that actually move the needle:

Use the payer's own clinical criteria language. Most payers publish their coverage policies online. Pull the actual PA criteria document for the drug you're requesting and mirror that language in your submission. If their policy says "moderate-to-severe disease as defined by a score of X or higher on [assessment tool]," include that score and that assessment tool. Don't make reviewers hunt for it.

Date everything. Every trial, every lab result, every office visit where the patient reported inadequate control needs a date. A PA reviewer can't approve step therapy failure they can't verify happened in a reasonable timeframe.

Include the "why now." If a patient has been on a medication for a year and you're reauthorizing, explain disease stability or why continued therapy is medically necessary. Don't assume the reviewer will connect those dots.

Building a Specialty PA Workflow That Doesn't Fall Apart

The practices that handle specialty PA volume well have one thing in common: they treat it as a dedicated workflow, not something that gets squeezed between other tasks. That sounds obvious, but many practices still handle specialty PA reactively: a prescription gets written, someone submits a PA request, and then everyone crosses their fingers.

A proactive approach looks different. Before a specialty medication is even prescribed, your team should be running an eligibility and benefit check to understand what that payer's requirements are going to be. If requests for a drug with a given payer often end up in peer-to-peer review, your physician needs to know that upfront, not after the first denial.

Consider building a specialty PA checklist by drug class that gets updated quarterly. This doesn't need to be elaborate. Even a simple shared document that lists the top 15 specialty drugs you prescribe, with the current payer-specific requirements, saves enormous time. Assign someone ownership of keeping it current. When you get a denial that reveals a changed requirement, update the checklist that day.

For practices with high specialty drug volume, a drafting tool can cut the time spent on first-level appeal letters. EZAppeal drafts appeal and prior-authorization letters in a few minutes, citing the payer's policy when one is on file, for your team to review and send. It does not replace the prescriber's clinical judgment.

When to Push Back: Denials That Shouldn't Stick

Not every denial deserves an appeal, but some absolutely do, and knowing the difference saves you from wasting time on appeals you'll lose while making sure you fight the ones you should win.

Appeals worth pursuing:

• Denials where the patient clearly meets criteria and documentation supports it. Sometimes things get denied because a reviewer missed something or the submission was incomplete. A targeted appeal that points to the missed evidence is the fix.
• Denials citing "not medically necessary" when clinical guidelines support the treatment. If NCCN guidelines, ACR recommendations, or other major clinical society guidelines back the prescribed therapy, say so explicitly and cite the specific guideline and publication date.
• Denials based on a step therapy requirement your patient already completed elsewhere. If a patient transferred to your practice and has prior treatment history with another provider, get those records and include them. You shouldn't have to re-fail a therapy that already failed.

Peer-to-peer requests from the prescribing physician are worth using, because a reviewer who hears the clinical history directly can weigh details a form doesn't capture. If your physicians are willing and the denial is worth fighting, get that call scheduled quickly and check how long the plan allows for requesting one.

Keeping Patients on Therapy During the PA Process

This is the part that keeps care coordinators up at night. A patient needs their biologic, the PA is pending, and you've got a gap to manage.

Manufacturer patient assistance programs and bridge supply programs exist specifically for this scenario. Many specialty drug manufacturers run hub services, support teams that may be able to provide bridge therapy while a PA is pending. These programs aren't always easy to find, but your specialty pharmacy partners should know them cold. Build that relationship with your specialty pharmacy rep if you haven't already.

For patients on Medicare, Extra Help (the Low-Income Subsidy) lowers Part D premiums, deductibles and cost-sharing, but it does not change a plan's prior authorization or step therapy criteria. When a Part D plan's step therapy or dose restriction blocks a drug the patient needs, the prescriber can request a formulary exception with a supporting statement (42 CFR 423.578(b)).

Next steps

Start now. Pull your specialty drug PA volume from the last six months, identify your top 10 drugs by submission frequency, and do a quick audit of current payer criteria for each one. Flag where requirements have changed and update your team before your next submissions. The practices that stay ahead of these changes protect their patients from therapy gaps and spend less time on rework. That's worth the prep time.